Depression rates in the United States have climbed relentlessly over the past three decades. While greater awareness and improved diagnostics account for part of the rise, the scale and demographic patterns remain striking. Rates have surged most dramatically among Asian and Black Americans since the 1990s, while increases in White
Modern drug development was built on the idea of treating the average patient. This model has worked reasonably well for conditions with clear, acute causes, but it struggles with chronic disease, where outcomes are shaped by the complex interplay of genetics, metabolism, and environment. By ignoring genetic diversity, the current
Military doctrine is shifting in real time. The war in Ukraine has shown the world that drones are now frontline weapons, altering battlefields and rewriting procurement strategies. The problem for Western defense contractors is obvious. Current systems are too expensive, too slow to adapt, and too dependent on foreign parts,
What if you could know your child’s health destiny from their very first breath? What if a simple swab at birth could reveal their genetic blueprint and allow you to give them the best possible start in life, preventing decades of chronic disease before they even begin? The future
Acetaminophen, America’s go-to pain and fever reducer, is not as safe as the public has been led to believe. For decades, doctors have handed it out freely, even to pregnant women, calling it the “safe choice.” But new genetic and biochemical evidence shows that for millions of mothers and
The war in Ukraine drags on, and Vladimir Putin continues to show defiance despite mounting pressure. President Trump tried diplomacy once, but Putin spit in his face. That time has passed. If Trump wants to end this war on his terms, he does not need to punish China or India
Over the past two years, GLP-1 receptor agonists, Ozempic, Wegovy, Mounjaro, have reshaped the healthcare landscape. These drugs are not just diet aids; they represent a paradigm shift in obesity management, diabetes care, and even cardiovascular risk reduction. They are, by every measure, blockbuster medicines. But success has brought with
August played out almost exactly as projected. The S&P 500 rose 1.9% for the month, versus the model’s forecast of +1.5%. The Dow climbed 3.2% as UnitedHealth reversed course and rebounded. The Russell 2000 outperformed as breadth returned to the market, just as anticipated.
We believe structural changes under new U.S. policies are setting the stage for the next leg of one of the greatest bull markets in history. The Clarity Act, the new FASB accounting rules effective in 2025, and the introduction of a 2.5% in-kind trade tax are catalysts that
The rise of cryptocurrency has rapidly moved from the fringes of finance into the very center of global capital markets. The launch of spot Bitcoin and Ethereum ETFs on U.S. exchanges such as the NYSE, Nasdaq, and CBOE has fundamentally changed how institutions, asset managers, and retail investors access
Modern farming has come to rely heavily on herbicides and fungicides, with glyphosate, marketed as Roundup, being the most widely used. The prevailing narrative is that the danger lies in chemical residues left on food, but the deeper and more insidious problem is what these chemicals do to the plants
The male fertility crisis is a growing, invisible epidemic that threatens future generations. While many people believe that the declining rates of reproduction are simply a lifestyle choice, an increasing number of people opting out of having children, the reality is far darker. The cause isn't a conscious
In February, I argued that 2025 would rhyme with 1926 — the year when a volatile, skeptical market finally launched into the vertical phase of one of history’s greatest bull runs. That view has only strengthened as the months pass. July landed close to my forecast of ~4% gains, with
Over the past two decades, rates of early-onset cancers have climbed at an alarming pace. Young adults under 50 are being diagnosed with colon, pancreatic, breast, and brain cancers at rates not seen in previous generations. While lifestyle changes and processed food consumption are frequently blamed, a growing body of
Non‑alcoholic fatty liver disease (NAFLD) and alcoholic liver disease (ALD) have emerged as silent epidemics in the United States, affecting tens of millions of people, often without symptoms until advanced stages. These conditions do not develop in a vacuum. Instead, they are driven by a complex interplay between genetics,
In February, I wrote that 2025 would rhyme with 1926, the year when a volatile, skeptical market finally launched into the vertical phase of one of history’s greatest bull runs. By mid-year, that forecast has held: the spring correction shook out the weak hands, and U.S. equities have
Over the past two decades, breast cancer has surged in unexpected ways—particularly among young Asian American women. Once considered a lower-risk group, Asian American and Pacific Islander (AAPI) women are now seeing some of the fastest increases in breast cancer incidence in the United States. According to recent data,
Over the past 15 years, early-onset colorectal cancer (EOCRC), once a medical rarity, has exploded into a global public health crisis. Rates are climbing across nearly every major country, particularly among individuals aged 15 to 40. In fact, colorectal cancer is now on track to become the most diagnosed cancer
U.S. healthcare spending is on track to hit $7.7 trillion by 2032, a staggering and unsustainable figure. Yet emerging technologies in genetic stratification, remote biomarker monitoring, artificial intelligence, and targeted nutrition offer a potential paradigm shift. These tools offer a blueprint for cutting healthcare costs by as much
In today’s health care economy, there’s an uncomfortable truth that few want to say out loud: curing a patient is bad for business. The pharmaceutical industry, valued at over $1.5 trillion in 2023, is designed not to eliminate disease, but to manage it. Most new drugs approved
The markets are already amid an powerful bull market, that was initiated and carried along by the commercialization of Artificial Intelligence and large language models. However, it seems that the bull run is about to be accelerated by the convergence of AI, along with tokenization and quantum computing. Each has
When I first argued that 2025 would echo 1926, the bold claim centered on the markets. But now, it’s clear this isn’t just a bull market analog—it’s a geopolitical one too. Just like in the mid-1920s, the world is entering a lull in global conflict, a
Read the original forecast from February: https://ceobloc.com/blog/is-2025-the-next-1926-a-historic-bull-market-forecast As we cross into the second half of 2025, the stock market is increasingly validating a forecast that seemed bold at the start of the year: we are living through the modern equivalent of the "Roaring 1920s."
America is in the middle of a metabolic collapse. Over the past sixty years, obesity rates have more than tripled, and chronic diseases like diabetes, heart disease, and autoimmune disorders have become widespread. The usual explanations, overeating, sedentary lifestyles only scratch the surface. A deeper, largely ignored culprit is at